Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma

2024

New Gene Signature for Lung Cancer Prognosis

Sample size: 420 publication 10 minutes Evidence: high

Author Information

Author(s): Xiang Huihui, Kasajima Rika, Azuma Koichi, Tagami Tomoyuki, Hagiwara Asami, Nakahara Yoshiro, Saito Haruhiro, Igarashi Yuka, Wei Feifei, Ban Tatsuma, Yoshihara Mitsuyo, Nakamura Yoshiyasu, Sato Shinya, Koizume Shiro, Tamura Tomohiko, Sasada Tetsuro, Miyagi Yohei

Primary Institution: Kanagawa Cancer Center Research Institute, Yokohama, Japan

Hypothesis

The expression of genes associated with amino acid metabolism can predict overall survival in lung adenocarcinoma patients.

Conclusion

The PTAAMG-Sig effectively predicts overall survival, drug sensitivity, and immunotherapy outcomes in lung adenocarcinoma patients.

Supporting Evidence

The PTAAMG-Sig model effectively stratified overall survival in lung adenocarcinoma patients.
High-risk patients had a significantly higher TP53 mutation rate.
PTAAMG-Sig predicted responses to chemotherapy and immunotherapy.
Patients with high PTAAMG-Sig risk scores had lower concentrations of plasma-free α-aminobutyric acid.
Validation in independent cohorts confirmed the robustness of the PTAAMG-Sig model.
PTAAMG-Sig was associated with immune cell infiltration in the tumor microenvironment.
Statistical analyses showed significant differences in survival outcomes based on PTAAMG-Sig risk scores.
PTAAMG-Sig was an independent predictor of overall survival.

Takeaway

Researchers found a new way to predict how long lung cancer patients might live by looking at certain genes related to how their bodies use amino acids.